


Improved Vaccine and Therapeutic Performance without the Jab



PHARMAJET'S NEEDLE-FREE INJECTION SYSTEMS

deliver a spring-powered injection in 1/10th of a second by means of a narrow stream of fluid that penetrates the skin with a precise dose and depth.

NO needle

NO external power source

- Fixed volumes
(variable dose devices in development)

Tropis® ID 0.1 ml Intradermal Injections




INJECTOR



SYRINGE



ADAPTER




ID injection with Tropis

Stratis® IM/SC 0.5 ml Intramuscular or Subcutaneous Injections



INJECTOR




RESET STATION



SYRINGE



ADAPTER



IM/SC injection with Stratis

Improved Performance




Faster to Market



Delighted Users

- DNA
- mRNA
- intradermal
- Save money
- Smiling babies
- Happy parents
- Commercialized
- Scaled manufacturing

Intradermal Delivery with Tropis



Mantoux Technique



- Technically difficult
- Slow
- Painful



Needle-Free Technique




- Simple
- *Very* rapid (<0.1 sec)
- Consistent



Tropis®



- Spring-powered
- Handheld, provides safe, fast and easy 0.1 ml administration to the intradermal layer
- CE Mark; 1st and only needle-free system with WHO Prequalification



PERFORMANCE QUALITY SAFETY

Needle-free Makes Pharma Products Perform Better

55+
Development
Partners

80+
Studies in
Progress

65+
Completed
Studies

Many Applications:

- Vaccines
- Therapeutics
- Select drug products

Any Level of Research:

- Bench testing
- Preclinical animal studies
- Clinical trials

Any Formulation:

- Viscosity up to 70 cP (mineral oil)
- Can use adjuvants and microcarriers
- Can do multiple injections per timepoint for larger doses



Nucleic Acid



Inactivated



Subunit



Live Attenuated



Viral Vector



Bacteria

PIPELINE

PRECLINICAL ANIMAL STUDIES

RESPIRATORY VIRUSES

- COVID-19 (15 studies)
- Influenza (4 studies)
- Pandemic Influenza
- Swine Influenza

ARBOVIRUSES

- Crimean Congo Hemorrhagic Fever
- Yellow Fever
- VEEV
- Zika


OTHER VIRUSES

- Hantaviruses
- Hepatitis B
- HIV / SIV (3 studies)
- Marburg Virus
- PRRSV
- Smallpox

CANCER & OTHER

- Canine Cancer
- Multiple Cancers (2 studies)
- Alzheimer's

CLINICAL TRIALS WITH PHARMAJET NFIS



PharmaJet[®]

Needle-Free Injection[™]



Manufacturing:


- International, redundant GMP production, assembly, packaging, and sterilization
- Partners in Singapore, US, and India
- 300M capacity
- Additional capacity easily added: PharmaJet retains all designs and validations


Future directions:

- Variable dose devices under development
- Pre-filling prototyped and demonstrated

Goals

- Increase pipeline 3x in 2 years
- 2 new pharma products to market in 3 years





THANK YOU



PharmaJet[®]
Needle-Free Injection[™]



Chris Cappello,
President and Chief Executive Officer

Chris.Cappello@PharmaJet.com



Darin Zehrung, MBA
Chief Business Development Officer

Darin.Zehrung@PharmaJet.com



Erin K. Spiegel, Ph.D.
Vice President, Clinical and Regulatory Affairs

Erin.Spiegel@PharmaJet.com



Paul LaBarre, MBA
Vice President, Global Business Development

Paul.LaBarre@PharmaJet.com